rejuvenail anti-fungal nail lacquer ciclopirox 80mg/g solution bottle
a menarini australia pty ltd - ciclopirox, quantity: 80 mg/g - solution - excipient ingredients: ethyl acetate; purified water; ethanol; hydroxypropyl chitosan; cetostearyl alcohol - for the topical treatment of mild to moderate onychomycoses, without lunular involvement, due to dermatophytes, yeasts and moulds.
imunorix
doppel farmaceutici s.r.l. - pidotimod - solution oral - 400mg/7ml
vaginorm-c
artesan pharma gmbh & co. kg - ascorbic acid - tablets vaginal - 250mg
macmiror tablets coated
doppel farmaceutici s.r.l. - nifuratel - tablets coated - 200mg
macmiror complex capsules vaginal soft
doppel farmaceutici s.r.l. - nifuratel, nystatin - capsules vaginal soft - 500mg+ 200 000iu
macmiror complex cream vaginal
doppel farmaceutici s.r.l. - nifuratel, nystatine - cream vaginal - 10g/100g+ 4000000iu/100g
dbl vincristine sulfate 1mg/1ml injection vial
pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma
epirubicin hydrochloride injection 50 mg/25 ml (9)
pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - farmorubicina has shown to be effective in a wide range of neoplastic diseases such as: - breast carcinoma. - soft tissue sarcoma - gastric carcinoma. - small cell lung carcinoma. - advanced ovarian carcinoma. farmorubicina may also be used in the treatment of transitional cell bladder carcinoma (ta/t1 and carcinoma in situ) and in the prophylaxis of the rebound of transitional cell bladder tumours with complete transurethral resection. farmorubicina may also be used alone as a single agent or as part of different kinds of polichemotherapy treatments.
navelbine 10 mg/ml concentrate for solution for infusion
pierre fabre ltd - vinorelbine tartrate - concentrate for solution for infusion - 10 base mg/ml - vinca alkaloids and analogues; vinorelbine
navelbine 10mg/1ml concentrate for solution for infusion vials
pierre fabre ltd - vinorelbine tartrate - solution for infusion - 10mg/1ml